Immuron (IMRN) Free Cash Flow (2016 - 2024)
Immuron (IMRN) posted quarterly Free Cash Flow of -$2.6 million for Q4 2024, down 100.19% year-over-year from $1.3 billion in Q1 2024, and down 100.19% quarter-over-quarter from -$1.3 million in Q4 2023.
Immuron (IMRN) Free Cash Flow (2016 - 2024) Analysis & Trends
Immuron's Free Cash Flow history runs 9 years deep, the most recent figure standing at -$2.6 million for Q4 2024.
- In Q4 2024, Free Cash Flow fell 100.19% year-over-year to -$2.6 million; the TTM figure through Sep 2025 stood at -$2.6 million (down 100.19% YoY), while the FY2025 annual figure was -$3.1 million, up 47.27% from the prior year.
- Free Cash Flow for Q4 2024 stood at -$2.6 million, down from -$1.3 million in the prior quarter.
- The five-year high for Free Cash Flow was $6332.7 in Q4 2021, with the low at -$3.1 million in Q2 2021.
- The 5-year median for Free Cash Flow is -$2.0 million (2023), against an average of -$1.7 million.
- The sharpest annual moves came in 2021 and 2023: Free Cash Flow jumped 100.23% in 2021, then sank 98291.95% in 2023.
- Immuron's Free Cash Flow stood at -$2.7 million in 2020, then surged by 100.23% to $6332.7 in 2021, then plunged by 79.02% to $1328.5 in 2022, then plunged by 98291.95% to -$1.3 million in 2023, then plunged by 100.19% to -$2.6 million in 2024.
- Business Quant data shows IMRN's Free Cash Flow at -$2.6 million in Q4 2024, -$1.3 million in Q4 2023, and -$2.0 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Immuron | 6.75 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.61 Mn |
| Dec 31, 2024 | -2.61 Mn |
| Dec 31, 2023 | -1.30 Mn |
| Dec 31, 2023 | -1.30 Mn |
| Jun 30, 2023 | -2.01 Mn |
| Jun 30, 2023 | -2.01 Mn |
| Dec 31, 2022 | 1,328.50 |
| Dec 31, 2022 | 1,328.50 |
| Jun 30, 2022 | -1.90 Mn |
| Jun 30, 2022 | -1.90 Mn |
| Dec 31, 2021 | 6,332.69 |
| Dec 31, 2021 | 6,332.69 |
| Jun 30, 2021 | -3.11 Mn |
| Jun 30, 2021 | -3.11 Mn |
| Dec 31, 2020 | -2.70 Mn |
| Dec 31, 2020 | -2.70 Mn |
| Jun 30, 2020 | -2.07 Mn |
| Jun 30, 2020 | -2.07 Mn |
| Dec 31, 2019 | -1.56 Mn |
| Dec 31, 2019 | -1.56 Mn |